|
1
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the last 25 years. J Nat Prod.
70:461–477. 2007.PubMed/NCBI
|
|
2
|
Laster LL and Lobene RR: New perspectives
on sanguinaria clinicals: individual toothpaste and oral rinse
testing. J Can Dent Assoc. 56:19–30. 1990.
|
|
3
|
Firatli E, Unal T, Onan U, et al:
Antioxidative activities of some chemotherapeutics. A possible
mechanism in reducing gingival inflammation. J Clin Periodontol.
21:680–683. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmad N, Gupta S, Husain MM, et al:
Differential antiproliferative and apoptotic response of
sanguinarine for cancer cells versus normal cells. Clin Cancer Res.
6:1524–1528. 2000.PubMed/NCBI
|
|
5
|
Weerasinghe P, Hallock S and Liepins A:
Bax, Bcl-2, and NF-kappaB expression in sanguinarine induced
bimodal cell death. Exp Mol Pathol. 71:89–98. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weerasinghe P, Hallock S, Tang SC, et al:
Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced
bimodal cell death. Cell Biol Toxicol. 17:371–381. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adhami VM, Aziz MH, Reagan-Shaw SR, et al:
Sanguinarine causes cell cycle blockade and apoptosis of human
prostate carcinoma cells via modulation of cyclin kinase
inhibitor-cyclin-cyclin-dependent kinase machinery. Mol Cancer
Ther. 3:933–940. 2004.
|
|
8
|
Ahsan H, Reagan-Shaw S, Breur J, et al:
Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1
and BxPC-3cells via modulations in Bcl-2 family proteins. Cancer
Lett. 249:198–208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matkar SS, Wrischnik LA and
Hellmann-Blumberg U: Sanguinarine causes DNA damage and
p53-independent cell death in human colon cancer cell lines. Chem
Biol Interact. 172:63–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim S, Lee TJ, Leem J, et al:
Sanguinarine-induced apoptosis: generation of ROS, down-regulation
of Bcl-2, c-FLIP, and synergy with TRAIL. J Cell Biochem.
104:895–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jang BC, Park JG, Song DK, et al:
Sanguinarine induces apoptosis in A549 human lung cancer cells
primarily via cellular glutathione depletion. Toxicol In vitro.
23:281–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
vrba J, Dolezel P, vicar J, et al:
Cytotoxic activity of sanguinarine and dihydrosanguinarine in human
promyelocytic leukemia HL-60 cells. Toxicol In vitro. 23:580–588.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park H, Bergeron E, Senta H, et al:
Sanguinarine induces apoptosis of human osteosarcoma cells through
the extrinsic and intrinsic pathways. Biochem Biophys Res Commun.
399:446–451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slaninová I, Táborská E, Bochoráková H, et
al: Interaction of benzo[c]phenanthridine and protoberberine
alkaloids with animal and yeast cells. Cell Biol Toxicol. 17:51–63.
2001.
|
|
15
|
Kaminskyy V, Lin KW, Filyak Y, et al:
Differential effect of sanguinarine, chelerythrine and chelidonine
on DNA damage and cell viability in primary mouse spleen cells and
mouse leukemic cells. Cell Biol Int. 32:271–277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Scarinci IC, Garcia FA, Kobetz E, et al:
Cervical cancer prevention: new tools and old barriers. Cancer.
116:2531–2542. 2010.PubMed/NCBI
|
|
17
|
Long HJ: Management of metastatic cervical
cancer: review of the literature. J Clin Oncol. 25:2966–2974. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding Z, Tang SC, Weerasinghe P, et al: The
alkaloid sanguinarine is effective against multidrug resistance in
human cervical cells via bimodal cell death. Biochem Pharmacol.
63:1415–1421. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Slunská Z, Gelnarová E, Hammerová J, et
al: Effect of quaternary benzo[c]phenanthridine alkaloids
sanguilutine and chelilutine on normal and cancer cells. Toxicol In
vitro. 24:697–706. 2010.
|
|
20
|
Adhami VM, Aziz MH, Mukhtar H, et al:
Activation of prodeath Bcl-2 family proteins and mithondrial
apoptosis pathway by sanguinarine in immortalized human HaCaT
keratinytes. ClinCancer Res. 9:3176–3182. 2003.PubMed/NCBI
|
|
21
|
Chaturvedi MM, Kumar A, Darnay BG, et al:
Sanguinarine(pseudhelerythrine) is a potent inhibitor of NF-kappaB
activation, IkappaBalpha phosphorylation, and degradation. J Biol
Chem. 272:30129–30134. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu S, Semenciw R, Probert A, et al:
Cervical cancer in Canada: changing patterns in incidence and
mortality. Int J Gynecol Cancer. 11:24–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laconi E, Pani P and Farber E: The
resistance phenotype in the development and treatment of cancer.
Lancet Oncol. 1:235–241. 2000. View Article : Google Scholar
|
|
24
|
Park JY, Kim DY, Kim JH, et al: Outcomes
after radical hysterectomy in patients with early-stage
adenocarcinoma of uterine cervix. Br J Cancer. 102:1692–1698. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quinn MA: Adenocarcinoma of the cervix -
are there arguments for a different treatment policy? Curr Opin
Obstet Gynecol. 9:21–24. 1997.PubMed/NCBI
|
|
26
|
Collins JA, Schandi CA, Young KK, et al:
Major DNA fragmentation is a late event in apoptosis. J Histochem
Cytochem. 45:923–934. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang MC, Chan CP, Wang YJ, et al:
Induction of necrosis and apoptosis to KB cancer cells by
sanguinarine is associated with reactive oxygen species production
and mitochondrial membrane depolarization. Toxicol Appl Pharmacol.
218:143–151. 2007. View Article : Google Scholar
|
|
28
|
Hussain AR, Al-Jomah NA, Siraj AK, et al:
Sanguinarine-dependent induction of apoptosis in primary effusion
lymphoma cells. Cancer Res. 67:3888–3897. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kajstura M, Halicka HD, Pryjma J and
Darzynkiewicz Z: Discontinuous fragmentation of nuclear DNA during
apoptosis revealed by discrete ‘sub-G1’ peaks on DNA content
histograms. Cytometry A. 71:125–131. 2007.PubMed/NCBI
|
|
30
|
McDonald ER III and El-Deiry WS: Cell
cycle control as a basis for cancer drug development (Review). Int
J Oncol. 16:871–886. 2000.PubMed/NCBI
|
|
31
|
Malikova J, Zdarilova A and Hlobilkova A:
Effects of sanguinarine and chelerythrine on the cell cycle and
apoptosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
150:5–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reed JC: Bcl-2: prevention of apoptosis as
a mechanism of drug resistance. Hematol Oncol Clin North Am.
9:451–473. 1995.PubMed/NCBI
|
|
33
|
Brady HJ and Gil-Gómez G: Bax. The
pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol.
30:647–650. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu ZW, Friess H, Büchler MW, et al:
Overexpression of Bax sensitizes human pancreatic cancer cells to
apoptosis induced by chemotherapeutic agents. Cancer Chemother
Pharmacol. 49:504–510. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heafner B: NF-kappa B: arresting a major
culprit in cancer. Drug Discov Today. 7:653–663. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:153–159. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mendoza J, Zamora R, Gallardo JC, et al:
NF-kappaB does not influence the induction of apoptosis by Ukrain.
Cancer Biol Ther. 5:788–793. 2006. View Article : Google Scholar : PubMed/NCBI
|
